Genetic testing

/Genetic testing

Did You Know That Metastatic Prostate Cancer Causes DNA Mutations?

Men with metastatic prostate cancer have higher rates of inherited gene mutations than men with non-metastatic prostate cancer.  Knowing about DNA mutations might help you make better treatment decisions. And you can also tell family members about their risk. Recent studies have shown that metastatic prostate cancer inherited mutations in the DNA-repair genes, such as the BRCA gene, can help guide treatment decisions as well as increase cancer risk in their family members. These mutations are more common in men with metastatic prostate cancer compared with men whose prostate cancer hasn’t spread outside the prostate gland. Men with advanced, metastatic prostate cancer should ask to be [...]

Oncotype DX® Now Validated for Adverse Pathology, Biochemical Recurrence, Metastasis and Prostate Cancer Specific Death

In a press release issued yesterday, Genomic Health Inc. announced topline results from their clinical validation study of its biopsy-based Oncotype DX® Genomic Prostate Score™ (GPS). The study met its primary endpoint by demonstrating that Oncotype DX® test is a strong predictor for the development of metastasis and also prostate cancer death in men with early-stage prostate cancer. The test evaluates the genetic makeup of tumor tissue taken from prostate biopsies. The Oncotype DX test has now been validated for adverse pathology, biochemical recurrence, metastasis and prostate cancer-specific death. According to a statement issued by Phil Febbo, M.D., the chief medical officer, Genomic Health, [...]

A New Genetic Test To Help You Understand Your Risk For A Prostate Cancer Recurrence

Base on a recently published news release, a prospective study performed and funded by the commercial company GenomeDx Biosciences showed that their new Decipher Cancer Classifier test reclassifies the tumor aggressiveness in men who have had surgery as their primary prostate cancer treatment. According to the company, this newly validated test will improve clinical decision-making following a radical prostatectomy. In this validation study, their Decipher Post-Op test was able to reclassified the tumor aggressiveness in a large number of men based on the genomic risk assessment as compared to our current clinical and pathological risk assessment tools. The company claims [...]